Consensus nomenclature rules for radiopharmaceutical chemistry - Setting the record straight

被引:149
作者
Coenen, Heinz H. [1 ]
Gee, Antony D. [2 ]
Adam, Michael [3 ]
Antoni, Gunnar [4 ]
Cutler, Cathy S. [5 ]
Fujibayashi, Yasuhisa [6 ]
Jeong, Jae Min [7 ]
Mach, Robert H. [8 ]
Mindt, Thomas L. [9 ]
Pike, Victor W. [10 ]
Windhorst, Albert D. [11 ]
机构
[1] Res Ctr Julich, Julich, Germany
[2] Kings Coll London, London, England
[3] TRIUMF, Vancouver, BC, Canada
[4] Uppsala Univ, Uppsala, Sweden
[5] Brookhaven Natl Lab, Upton, NY 11973 USA
[6] Keio Univ, Tokyo, Japan
[7] Seoul Natl Univ, Seoul, South Korea
[8] Univ Penn, Philadelphia, PA 19104 USA
[9] Ludwig Boltzmann Inst Appl Diagnost, Vienna, Austria
[10] NIMH, Bethesda, MD 20892 USA
[11] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
关键词
Nomenclature; Terminology; Consensus guidelines; Radiopharmaceutical sciences; Nuclear chemistry; Radiochemistry; CARRIER;
D O I
10.1016/j.nucmedbio.2017.09.004
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Over recent years, within the community of radiopharmaceutical sciences, there has been an increased incidence of incorrect usage of established scientific terms and conventions, and even the emergence of 'self-invented' terms. In order to address these concerns, an international Working Group on 'Nomenclature in Radiopharmaceutical Chemistry and related areas' was established in 2015 to achieve clarification of terms and to generate consensus on the utilisation of a standardised nomenclature pertinent to the field. Upon open consultation, the following consensus guidelines were agreed, which aim to: Provide a reference source for nomenclature good practice in the radiopharmaceutical sciences. Clarify the use of terms and rules concerning exclusively radiopharmaceutical terminology, i.e. nuclear-and radiochemical terms, symbols and expressions. Address gaps and inconsistencies in existing radiochemistry nomenclature rules. Provide source literature for further harmonisation beyond our immediate peer group (publishers, editors, IUPAC, pharmacopoeias, etc.). (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:V / XI
页数:7
相关论文
共 15 条
  • [1] [Anonymous], 1994, PURE APPL CHEM, V66, P2513
  • [2] Bonardi ML, 2014, TERMINOLOGY CARRIER
  • [3] N.C.A. RADIOSYNTHESIS OF [I-123,I-124]BETA-CIT, PLASMA ANALYSIS AND PHARMACOKINETIC STUDIES WITH SPECT AND PET
    COENEN, HH
    DUTSCHKA, K
    MULLER, SP
    GEWORSKI, L
    FARAHATI, J
    REINERS, C
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1995, 22 (08): : 977 - 984
  • [4] How do we define the concepts specific activity, radioactive concentration, carrier, carrier-free and no-carrier-added?
    de Goeij, JJM
    Bonardi, ML
    [J]. JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2005, 263 (01) : 13 - 18
  • [5] GLOSSARY OF TERMS USED IN NUCLEAR ANALYTICAL-CHEMISTRY
    DEBRUIN, M
    [J]. PURE AND APPLIED CHEMISTRY, 1982, 54 (08) : 1533 - 1554
  • [6] True radiotracers: are we approaching theoretical specific activity with Tc-99m and I-123?
    Eckelman, William C.
    Volkert, Wynn A.
    Bonardi, Mauro
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2008, 35 (05) : 523 - 527
  • [7] Fennel RW, 1994, HIST IUPAC 1919 1987
  • [8] Factors affecting the specific activity of [18F]fluoride from a [18O] water target
    Fuechtner, F.
    Preusche, S.
    Maeding, P.
    Zessin, J.
    Steinbach, J.
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2008, 47 (03): : 116 - 119
  • [9] A historical perspective on the specific activity of radiopharmaceuticals: What have we learned in the 35 years of the ISRC?
    Lapi, Suzanne E.
    Welch, Michael J.
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2013, 40 (03) : 314 - 320
  • [10] MANN WB, 1986, NUCL MED BIOL, V13, P1